Evonik considers potential BASF takeover and Ashland acquisition

Evonik is reportedly evaluating two distinct strategic paths involving major transactions. Media reports from Handelsblatt and Reuters suggest that BASF has increased its takeover offer for Evonik to approximately 24 euros per share, totaling more than 11 billion euros. While Evonik is reportedly reviewing this offer, no merger has been finalized.

Separately, reports indicate that Evonik may be considering a multi-billion dollar acquisition in the United States, specifically targeting the specialty chemicals company Ashland. Evonik has maintained a policy of not commenting on market rumors, and there is no confirmed link between the potential BASF takeover and the possible Ashland purchase.

In its medical systems division, Evonik has confirmed the launch of two new PEEK (polyetheretherketone) material grades, Vestakeep DC4760 and Vestakeep DC4780. These materials are designed for long-term dental prosthetics, offering increased rigidity and flexural strength. The new grades are intended for both fixed and removable restorations, particularly those subject to high loads, such as implant-supported prostheses.